JP2019504104A5 - - Google Patents

Download PDF

Info

Publication number
JP2019504104A5
JP2019504104A5 JP2018540806A JP2018540806A JP2019504104A5 JP 2019504104 A5 JP2019504104 A5 JP 2019504104A5 JP 2018540806 A JP2018540806 A JP 2018540806A JP 2018540806 A JP2018540806 A JP 2018540806A JP 2019504104 A5 JP2019504104 A5 JP 2019504104A5
Authority
JP
Japan
Prior art keywords
alkyl
group
compound
substituted
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018540806A
Other languages
English (en)
Japanese (ja)
Other versions
JP6735837B2 (ja
JP2019504104A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/050568 external-priority patent/WO2017134596A1/en
Publication of JP2019504104A publication Critical patent/JP2019504104A/ja
Publication of JP2019504104A5 publication Critical patent/JP2019504104A5/ja
Application granted granted Critical
Publication of JP6735837B2 publication Critical patent/JP6735837B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018540806A 2016-02-04 2017-02-02 Hiv−1阻害剤としてのc−3およびc−17修飾トリテルペノイド Active JP6735837B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662291298P 2016-02-04 2016-02-04
US62/291,298 2016-02-04
PCT/IB2017/050568 WO2017134596A1 (en) 2016-02-04 2017-02-02 C-3 and c-17 modified triterpenoids as hiv-1 inhibitors

Publications (3)

Publication Number Publication Date
JP2019504104A JP2019504104A (ja) 2019-02-14
JP2019504104A5 true JP2019504104A5 (enExample) 2020-01-30
JP6735837B2 JP6735837B2 (ja) 2020-08-05

Family

ID=57995251

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018540806A Active JP6735837B2 (ja) 2016-02-04 2017-02-02 Hiv−1阻害剤としてのc−3およびc−17修飾トリテルペノイド

Country Status (39)

Country Link
US (4) US10421774B2 (enExample)
EP (2) EP3831839B1 (enExample)
JP (1) JP6735837B2 (enExample)
KR (1) KR102795662B1 (enExample)
CN (1) CN109153700B (enExample)
AR (1) AR107512A1 (enExample)
AU (1) AU2017215529B2 (enExample)
BR (1) BR112018015629B1 (enExample)
CA (1) CA3013417C (enExample)
CL (1) CL2018002084A1 (enExample)
CO (1) CO2018008157A2 (enExample)
CR (1) CR20180387A (enExample)
CY (1) CY1124353T1 (enExample)
DK (1) DK3411381T3 (enExample)
DO (1) DOP2018000174A (enExample)
EA (1) EA036211B1 (enExample)
ES (2) ES2957767T3 (enExample)
HR (1) HRP20210502T1 (enExample)
HU (1) HUE054337T2 (enExample)
IL (1) IL260741B (enExample)
JO (1) JOP20170029B1 (enExample)
LT (1) LT3411381T (enExample)
MA (2) MA53358A (enExample)
MD (1) MD3411381T2 (enExample)
MX (1) MX375118B (enExample)
MY (1) MY199668A (enExample)
PE (1) PE20181355A1 (enExample)
PL (1) PL3411381T3 (enExample)
PT (1) PT3411381T (enExample)
RS (1) RS61746B1 (enExample)
RU (1) RU2716502C2 (enExample)
SG (1) SG11201806388XA (enExample)
SI (1) SI3411381T1 (enExample)
SM (1) SMT202100210T1 (enExample)
TW (1) TWI719126B (enExample)
UA (1) UA123867C2 (enExample)
UY (1) UY37109A (enExample)
WO (1) WO2017134596A1 (enExample)
ZA (1) ZA201805044B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR107512A1 (es) * 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
EP4321164A3 (en) 2018-04-24 2024-04-17 ViiV Healthcare UK (No.5) Limited Compounds with hiv maturation inhibitory activity
MX2022006940A (es) 2019-12-09 2022-07-11 Viiv Healthcare Co Composiciones farmaceuticas.
WO2025068743A1 (en) 2023-09-27 2025-04-03 ViiV Healthcare UK (No.3) Limited Pharmaceutical composition of cabotegravir
WO2024089216A1 (en) 2022-10-27 2024-05-02 Syngenta Crop Protection Ag Novel sulfur-containing heteroaryl carboxamide compounds
WO2025037232A1 (en) 2023-08-11 2025-02-20 ViiV Healthcare UK (No.4) Limited Tosylate salt form of a maturation inhibitor for treatment of hiv
US20250099464A1 (en) 2023-09-27 2025-03-27 ViiV Healthcare UK (No.3) Limited Pharmaceutical compositions

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
GB0301227D0 (en) 2003-01-20 2003-02-19 Keen Group Ltd Seating apparatus
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
MXPA06010592A (es) 2004-03-17 2007-06-12 Panacos Pharmaceuticals Inc Sales farmaceuticas de acido 3-o-(3',3'-dimetilsuccinil) betulinico.
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
US20110144069A1 (en) 2006-10-16 2011-06-16 Myriad Genetics, Incorporated Compounds for treating viral infections
EP2257567A1 (en) 2008-02-14 2010-12-08 Virochem Pharma Inc. Novel 17 beta lupane derivatives
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
FR2956034B1 (fr) 2010-02-09 2012-02-10 Thales Sa Dispositif d'entrainement pour des joueurs de rugby
MX2012013628A (es) 2010-06-04 2012-12-17 Bristol Myers Squibb Co Amidas c-28 de derivados del acido betulinico c-3 modificados como inhibidores de la maduracion del virus de inmunodeficiencia humana (vih).
CN103038245B (zh) 2010-06-04 2015-03-25 百时美施贵宝公司 作为hiv成熟抑制剂的c-3经修饰的桦木酸衍生物
DE102010017786A1 (de) 2010-07-07 2012-01-12 Continental Reifen Deutschland Gmbh Elastomerprodukt, enthaltend ein linienförmiges, textiles Gebilde zur Verstärkung
US8846647B2 (en) 2011-01-31 2014-09-30 Bristol-Myers Squibb Company C-17 and C-3 modified triterpenoids with HIV maturation inhibitory activity
RS54352B1 (sr) 2011-01-31 2016-02-29 Bristol-Myers Squibb Company C-28 amini c-3 modifikovanih derivata betulinske kiseline kao inhibitori sazrevanja hiv-a
ES2584684T3 (es) * 2011-12-14 2016-09-28 Glaxosmithkline Llc Derivados de propenoato de betulina
US8906889B2 (en) * 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
US8889854B2 (en) * 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
JP2016505000A (ja) 2012-12-21 2016-02-18 エピザイム,インコーポレイティド Prmt5阻害剤およびその使用
US9378035B2 (en) 2012-12-28 2016-06-28 Commvault Systems, Inc. Systems and methods for repurposing virtual machines
SG11201505639SA (en) * 2013-02-06 2015-08-28 Bristol Myers Squibb Co C-19 modified triterpenoids with hiv maturation inhibitory activity
MX2015010354A (es) * 2013-02-25 2015-10-09 Squibb Bristol Myers Co Derivados de acido betulinico modificados con aquilo c-3 y alquenilo utiles en el tratamiento de virus de inmunodeficiencia humana (vih).
CN104877015B (zh) * 2014-02-28 2019-02-01 中国人民解放军军事医学科学院毒物药物研究所 一种三萜-多肽缀合物、其药物组合物及用途
PL3129392T3 (pl) * 2014-04-11 2021-04-06 VIIV Healthcare UK(No.4) Limited Triterpenoidy o aktywności hamującej dojrzewanie hiv, podstawione w pozycji 3 niearomatycznym pierścieniem zawierającym podstawnik fluorowcoalkilowy
MA40886B1 (fr) 2015-02-09 2020-03-31 Hetero Research Foundation Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
AR107512A1 (es) * 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
DK3984994T3 (da) 2016-02-04 2024-10-14 Takeda Pharmaceuticals Co Substitueret piperidinforbindelse som orexin-type 2-agonist til behandling af narkolepsi

Similar Documents

Publication Publication Date Title
JP2019504104A5 (enExample)
JP2014507422A5 (enExample)
RU2018130181A (ru) C-3 и C-17 модифицированные тритерпеноиды в качестве ингибиторов ВИЧ-1
JP2016507558A5 (enExample)
JP2016518437A5 (enExample)
WO2019143902A3 (en) Substituted heterocycles as antiviral agents
JP2018510139A5 (enExample)
JP2017523225A5 (enExample)
JP2017504642A5 (enExample)
JP2019507774A5 (enExample)
JP2017537940A5 (enExample)
JP2015531773A5 (enExample)
BR9911043A (pt) Composição para o tratamento do hiv e outras infecções viróticas
MX2021003253A (es) Heterociclos funcionalizados como agentes antivirales.
JP2017512186A5 (enExample)
JP2019524883A5 (enExample)
WO2021055425A3 (en) Functionalized heterocycles as antiviral agents
JP2016506387A5 (enExample)
JP2002524503A5 (enExample)
JP2019528279A5 (enExample)
JP2003523927A5 (enExample)
KR900018037A (ko) 치환 (퀴놀린-2-일-메톡시)페닐-아실-술폰아미드 및-시안아미드, 그의 제조 방법 및 약제로서의 용도
JP2015512883A5 (enExample)
JP2017533937A5 (enExample)
JP2004531532A5 (enExample)